BACKGROUND: A set of common cancer-related and treatment-related symptoms has been proposed for quality of care assessment and clinical research. Using data from a large, multicenter, prospective study, the authors assessed the effects of disease site and stage on the percentages of patients rating these proposed symptoms as moderate to severe. METHODS: The severity of 13 symptoms proposed to represent "core" oncology symptoms was rated by 3106 ambulatory patients with cancer of the breast, prostate, colon/rectum, or lung, regardless of disease stage or phase of care; 2801 patients (90%) repeated the assessment 4 to 5 weeks later. RESULTS: At the time of the initial assessment, approximately 33% of the patients reported ≥ 3 symptoms in the moderate-to-severe range; 11 of the 13 symptoms were rated as moderate to severe by at least 10% of all patients and 6 were rated as moderate to severe by at least 20% of those receiving active treatment. Fatigue/tiredness was the most severe symptom, followed by disturbed sleep, pain, dry mouth, and numbness/tingling. More patients with lung cancer and patients receiving active treatment reported moderate to severe symptoms. Percentages of symptomatic patients increased by disease stage, less adequate response to therapy, and declining Eastern Cooperative Oncology Group performance status. The percentages of patients reporting moderate to severe symptoms were stable across both assessments. CONCLUSIONS: The results of the current study support a core set of moderate to severe symptoms that are common across outpatients with solid tumors, that can guide consideration of progression-free survival as a trial outcome, and that should be considered in clinical care and in assessments of quality of care and treatment benefit.
BACKGROUND: A set of common cancer-related and treatment-related symptoms has been proposed for quality of care assessment and clinical research. Using data from a large, multicenter, prospective study, the authors assessed the effects of disease site and stage on the percentages of patients rating these proposed symptoms as moderate to severe. METHODS: The severity of 13 symptoms proposed to represent "core" oncology symptoms was rated by 3106 ambulatory patients with cancer of the breast, prostate, colon/rectum, or lung, regardless of disease stage or phase of care; 2801 patients (90%) repeated the assessment 4 to 5 weeks later. RESULTS: At the time of the initial assessment, approximately 33% of the patients reported ≥ 3 symptoms in the moderate-to-severe range; 11 of the 13 symptoms were rated as moderate to severe by at least 10% of all patients and 6 were rated as moderate to severe by at least 20% of those receiving active treatment. Fatigue/tiredness was the most severe symptom, followed by disturbed sleep, pain, dry mouth, and numbness/tingling. More patients with lung cancer and patients receiving active treatment reported moderate to severe symptoms. Percentages of symptomatic patients increased by disease stage, less adequate response to therapy, and declining Eastern Cooperative Oncology Group performance status. The percentages of patients reporting moderate to severe symptoms were stable across both assessments. CONCLUSIONS: The results of the current study support a core set of moderate to severe symptoms that are common across outpatients with solid tumors, that can guide consideration of progression-free survival as a trial outcome, and that should be considered in clinical care and in assessments of quality of care and treatment benefit.
Authors: Shauna L Hillman; Sumithra J Mandrekar; Brian Bot; Ronald P DeMatteo; Edith A Perez; Karla V Ballman; Heidi Nelson; Jan C Buckner; Daniel J Sargent Journal: J Clin Oncol Date: 2010-05-17 Impact factor: 44.544
Authors: Carolyn Miller Reilly; Deborah Watkins Bruner; Sandra A Mitchell; Lori M Minasian; Ethan Basch; Amylou C Dueck; David Cella; Bryce B Reeve Journal: Support Care Cancer Date: 2013-01-12 Impact factor: 3.603
Authors: Charles S Cleeland; Jeff A Sloan; David Cella; Connie Chen; Amylou C Dueck; Nora A Janjan; Astra M Liepa; Rajiv Mallick; Ann O'Mara; Jay D Pearson; Yasuhiro Torigoe; Xin Shelley Wang; Loretta A Williams; Jeanie F Woodruff Journal: Cancer Date: 2012-08-28 Impact factor: 6.860
Authors: Barbara Given; Charles W Given; Alla Sikorskii; Sangchoon Jeon; Ruth McCorkle; Victoria Champion; David Decker Journal: J Pain Symptom Manage Date: 2007-12-26 Impact factor: 3.612
Authors: Ethan Basch; Amy P Abernethy; C Daniel Mullins; Bryce B Reeve; Mary Lou Smith; Stephen Joel Coons; Jeff Sloan; Keith Wenzel; Cynthia Chauhan; Wayland Eppard; Elizabeth S Frank; Joseph Lipscomb; Stephen A Raymond; Merianne Spencer; Sean Tunis Journal: J Clin Oncol Date: 2012-10-15 Impact factor: 44.544
Authors: C S Cleeland; R Gonin; A K Hatfield; J H Edmonson; R H Blum; J A Stewart; K J Pandya Journal: N Engl J Med Date: 1994-03-03 Impact factor: 91.245
Authors: Xifeng Wu; Michelle At Hildebrandt; Yuanqing Ye; Wong-Ho Chow; Jian Gu; Sonia Cunningham; Hua Zhao; Ernest T Hawk; Elizabeth Wagar; Alma Rodriguez; Stanley R Hamilton Journal: Int J Epidemiol Date: 2015-12-20 Impact factor: 7.196
Authors: Goldy C George; Tito R Mendoza; Eucharia C Iwuanyanwu; Meryna Manandhar; Solmaz F Afshar; Sarina A Piha-Paul; Apostolia Tsimberidou; Aung Naing; Charles S Cleeland; David S Hong Journal: Invest New Drugs Date: 2019-11-25 Impact factor: 3.850
Authors: Qiuling Shi; Ju-Whei Lee; Xin Shelley Wang; Michael J Fisch; Victor T Chang; Lynne Wagner; Charles S Cleeland Journal: JCO Oncol Pract Date: 2020-05-05
Authors: Terri S Armstrong; Elizabeth Vera-Bolanos; Alvina A Acquaye; Mark R Gilbert; Harshad Ladha; Tito Mendoza Journal: Neuro Oncol Date: 2015-08-19 Impact factor: 12.300
Authors: Amy J Hoffman; Ruth Ann Brintnall; Barbara A Given; Alexander von Eye; Lee W Jones; Jean K Brown Journal: Cancer Nurs Date: 2017 Jan/Feb Impact factor: 2.592